ArticleFrontiers in immunology2022

Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma.

Jianlong Jia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.